Bio-Techne expands AI-engineered protein portfolio for cell therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
July 8, 2026 6:30 AM EDTAdvancing Scalable Reproducible Cell Therapy and Advanced Cell Culture Workflows
New heat-stable and hyperactive proteins across the fibroblast growth factor and interleukin cytokine families expand the R&D Systems AI-Engineered Designer Protein portfolioAI-guided protein design supports improved consistency, performance and scalability in complex cell culture workflows
Engineered signaling proteins help address key challenges in scaling cell therapy from discovery through manufacturing
MINNEAPOLIS, July 8, 2026 /PRNewswire/ --... More
